Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 5/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | TERT | O14746 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | PPARD | Q03181 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11507798 | 0.93 | FAAH (0.47) | FFAR1FFAR4FAAHTRPV1TERT | |
| SCHEMBL10583681 | 0.91 | FAAH (0.52) | FFAR1FFAR4FAAHTRPV1TERT | |
| SCHEMBL15015524 | 0.91 | FAAH (0.52) | FFAR1FFAR4FAAHTRPV1TERT | |
| SCHEMBL9467075 | 0.91 | FAAH (0.52) | FFAR1FFAR4FAAHTRPV1TERT | |
| SCHEMBL6465319 | 0.91 | FAAH (0.52) | FFAR1FFAR4FAAHTRPV1TERT | |
| SCHEMBL9467020 | 0.91 | FAAH (0.52) | FFAR1FFAR4FAAHTRPV1TERT | |
| SCHEMBL151797 | 0.91 | FAAH (0.52) | FFAR1FFAR4FAAHTRPV1TERT | |
| SCHEMBL6672341 | 0.91 | FAAH (0.52) | FFAR1FFAR4FAAHTRPV1TERT | |
| SCHEMBL9466962 | 0.89 | FAAH (0.50) | FFAR1FFAR4FAAHTRPV1TERT | |
| SCHEMBL9467790 | 0.87 | FAAH (0.48) | FFAR1FFAR4FAAHTRPV1TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100172967-A1 | COMPOUND MODIFIED WITH GLYCEROL DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-07-08 | — | — | US | disclosed |
| US-7696359-B2 | Compound modified with glycerol derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| US-20060280784-A1 | Compound modified with glycerol derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| EP-1666486-A1 | COMPOUND MODIFIED WITH GLYCEROL DERIVATIVE | Kyowa Hakko Kogyo Co., Ltd (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-0285178-B1 | Mannobiose derivatives | MEITO SANGYO KK (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0680974-A1 | Novel muramyldipeptide derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1995-11-08 | — | — | EP | disclosed |
| US-5292506-A | L-alanine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-03-08 | — | — | US | disclosed |
| EP-0348942-B1 | LIPID MEMBRANE STRUCTURES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1992-12-09 | — | — | EP | disclosed |
| US-5141751-A | Drug delivery for antitumor agent; mass-reproduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1992-08-25 | — | — | US | disclosed |
| EP-0487909-A2 | Novel muramyldipeptide derivatives and influenza vaccine comprising the derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1992-06-03 | — | — | EP | disclosed |
| US-4983725-A | Liposomes with affinity for liver cells | MEITO SANGYO CO., LTD. (JP) | 1991-01-08 | — | — | US | disclosed |
| EP-0348942-A2 | Lipid membrane structures | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060280784-A1 | Compound modified with glycerol derivative | MRGPRX1, MRGPRX2, NPC1L1 | FFAR1 632/4885FFAR4 704/4885FAAH 1915/4885 |
| US-20100172967-A1 | COMPOUND MODIFIED WITH GLYCEROL DERIVATIVE | NPC1L1, SGMS1, SCARB1 | FFAR1 543/4885FFAR4 650/4885FAAH 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.